medwireNews: Patients with urothelial carcinoma who have a high risk for recurrence following radical resection may be given nivolumab in the adjuvant setting, the US FDA has announced.
This decision is based on interim results of the phase 3 CheckMate 274 trial, demonstrating a significant disease-free survival (DFS) benefit with adjuvant nivolumab relative to placebo in this patient population, such that in the intention-to-treat analysis the risk for first recurrence or death was 30% lower with the PD-1 inhibitor. The median DFS times in the nivolumab and placebo groups were 20.8 and 10.8 months, respectively.
It is recommended that nivolumab be administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group